Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-06-11

FDA Approved: TRIJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TRIJARDY XR (empagliflozin, linagliptin, metformin hydrochloride) from Boehringer Ingelheim Pharmaceuticals, Inc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRIJARDY XR (Empagliflozin, Linagliptin, Metformin hydrochloride)

Snippet

SUPPL AP for TRIJARDY XR (EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE)